Philadelphia, PA - Successive increases in average erythropoietin (EPO) doses to alleviate anemia in end-stage renal-disease (ESRD) patients have occurred over the past 14 years in parallel with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback